Brief: JW (Cayman) Therapeutics Says It Got NMPA's IND Clearance For Pivotal Clinical Trial Of Carteyva
31/03/2022 09:16
March 31 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* RECEIVED IND CLEARANCE FROM CHINA'S NMPA FOR PIVOTAL
CLINICAL
TRIAL OF CARTEYVA
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics
See all newsChina's JW Therapeutics interim revenue rises 4.7% on Carteyva sales
China pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million